Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3454616 | 1.00 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7791059 | 0.97 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28291026 | 0.90 | ALDH1A1 (0.71) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL30359537 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL2396390 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3417188 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10896997 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL240402 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL842 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL725546 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017046709-A1 | BIOCIDES AND PREPARATION THEREOF | BIOLOGICAL CHEMICAL TECHNOLOGIES (PTY) LTD T/A BIODX (ZA) | 2017-03-23 | — | — | WO | claimed |
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | INSPIRMED CORP. (TW) | 2026-05-19 | — | — | US | disclosed |
| US-20230181615-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | INSPIRMED CORP (TW) | 2023-06-15 | — | — | US | disclosed |
| EP-4125810-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | InspirMed Corp. (TW) | 2023-02-08 | — | — | EP | disclosed |
| CN-115315252-A | Antiviral composition for preventing or treating infection or respiratory disease after exposure | 盈擘医药股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220211623-A1 | INHALABLE SUSTAINED RELEASE COMPOSITION OF BRONCHODILATOR FOR USE IN TREATING PULMONARY DISEASE | INSPIRMED CORP. (TW) | 2022-07-07 | — | — | US | disclosed |
| EP-3968951-A1 | INHALABLE SUSTAINED RELEASE COMPOSITION OF BRONCHODILATOR FOR USE IN TREATING PULMONARY DISEASE | Inspirmed Corp (TW) | 2022-03-23 | — | — | EP | disclosed |
| WO-2021194927-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | TLC BIOPHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2020232198-A1 | INHALABLE SUSTAINED RELEASE COMPOSITION OF BRONCHODILATOR FOR USE IN TREATING PULMONARY DISEASE | TLC BIOPARMACEUTICALS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3518878-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | Henkel AG & Co. KGaA (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| WO-2017046709-A1 | BIOCIDES AND PREPARATION THEREOF | BIOLOGICAL CHEMICAL TECHNOLOGIES (PTY) LTD T/A BIODX (ZA) | 2017-03-23 | — | — | WO | disclosed |
| US-7128976-B2 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, S100A10 | MEN1 3369/4885ALDH1A1 1010/4885HMGCR 3426/4885 |
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | IFNAR1, NPC1, SGMS1 | MEN1 3475/4885ALDH1A1 4342/4885HMGCR 66/4885 |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, SRRM2, IK | MEN1 4505/4885ALDH1A1 3629/4885HMGCR 2361/4885 |
| US-20230181615-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | LIPA, MAVS, ISG15 | MEN1 2858/4885ALDH1A1 3863/4885HMGCR 1863/4885 |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CD44, PCNA | MEN1 2001/4885ALDH1A1 1465/4885HMGCR 4250/4885 |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, DSG1 | MEN1 3038/4885ALDH1A1 1179/4885HMGCR 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.